Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    NCT01396239
Show Display Options
Rank Status Study
1 Completed Efficacy Study of AVI-4658 to Induce Dystrophin Expression in Selected Duchenne Muscular Dystrophy Patients
Condition: Duchenne Muscular Dystrophy
Intervention: Drug: AVI-4658 (Eteplirsen)

Indicates status has not been verified in more than two years